Literature DB >> 27824671

Early Changes of Irradiated Parotid Glands Evaluated by T1rho-Weighted Imaging: A Pilot Study.

Nan Zhou1, Chen Chu, Xin Dou, Ming Li, Song Liu, Tingting Guo, Lijing Zhu, Baorui Liu, Weibo Chen, Jian He, Jing Yan, Zhengyang Zhou, Xiaofeng Yang.   

Abstract

OBJECTIVE: The aim of the study was to confirm the feasibility of T1rho-weighted imaging to evaluate the dynamic changes of parotid glands in patients with nasopharyngeal carcinoma (NPC) undergoing intensity-modulated radiation therapy.
METHODS: Twenty-six NPC patients (19 men; 7 women; mean [SD] age, 48.9 [13.4] years) underwent the following 3 serial T1rho-weighted imaging: within 2 weeks before radiotherapy (RT, pre-RT), 5 weeks after the beginning of RT (mid-RT), and 4 weeks after RT (post-RT). Parotid volumes, T1rho values, mean radiation doses, and xerostomia degrees were recorded. Change rates of parotid T1rho values were correlated with parotid atrophy rates, mean radiation doses, and xerostomia degrees.
RESULTS: During RT, parotid volume decreased (atrophy rate, 32.7 [8.1%] at mid-RT and 27.9 [10.0%] at post-RT compared with pre-RT; both P < 0.001) and parotid T1rho values increased (change rate, 25.0 [15.8%] at mid-RT and 30.1 [18.0%] at post-RT compared with pre-RT, both P < 0.001) significantly. The change rate of parotid T1rho value correlated with the atrophy rate significantly at post-RT (r = 0.301, P = 0.047). Intraobserver and interobserver reproducibility of parotid T1rho measurements were excellent (intraclass correlation coefficient, 0.974 and 0.956, respectively).
CONCLUSIONS: Dynamic changes of radiation-induced parotid damage in NPC patients who underwent intensity-modulated radiation therapy could be noninvasively evaluated by T1rho-weighted imaging.

Entities:  

Mesh:

Year:  2017        PMID: 27824671     DOI: 10.1097/RCT.0000000000000547

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  7 in total

1.  Physiological variation of liver iron concentration may not be dominantly responsible for the liver T1rho variations associated with age and gender.

Authors:  Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2021-04

Review 2.  Repetitive MRI of organs at risk in head and neck cancer patients undergoing radiotherapy.

Authors:  Sonja Stieb; Baher Elgohari; Clifton David Fuller
Journal:  Clin Transl Radiat Oncol       Date:  2019-04-26

3.  Feasibility of DW-MRI analysis of salivary glands during head and neck radiotherapy.

Authors:  Aileen Duffton; Olivia Kemp; Lynsey Devlin; Lisa Hay; Philip McLoone; Claire Paterson
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-09-04

4.  T for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study.

Authors:  Ernst S Kooreman; Max Tanaka; Leon C Ter Beek; Femke P Peters; Corrie A M Marijnen; Uulke A van der Heide; Petra J van Houdt
Journal:  J Clin Med       Date:  2022-04-02       Impact factor: 4.241

Review 5.  MR-Guided Adaptive Radiotherapy for OAR Sparing in Head and Neck Cancers.

Authors:  Samuel L Mulder; Jolien Heukelom; Brigid A McDonald; Lisanne Van Dijk; Kareem A Wahid; Keith Sanders; Travis C Salzillo; Mehdi Hemmati; Andrew Schaefer; Clifton D Fuller
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

6.  Apparent diffusion coefficient histogram analysis can evaluate radiation-induced parotid damage and predict late xerostomia degree in nasopharyngeal carcinoma.

Authors:  Nan Zhou; Tingting Guo; Huanhuan Zheng; Xia Pan; Chen Chu; Xin Dou; Ming Li; Song Liu; Lijing Zhu; Baorui Liu; Weibo Chen; Jian He; Jing Yan; Zhengyang Zhou; Xiaofeng Yang
Journal:  Oncotarget       Date:  2017-07-26

7.  Salivary gland function in nasopharyngeal carcinoma before and late after intensity-modulated radiotherapy evaluated by dynamic diffusion-weighted MR imaging with gustatory stimulation.

Authors:  Dai Shi; Jian-Jun Qian; Guo-Hua Fan; Jun-Kang Shen; Ye Tian; Liang Xu
Journal:  BMC Oral Health       Date:  2019-12-21       Impact factor: 2.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.